Skip to main content
. 2020 Sep 19;2020:4176376. doi: 10.1155/2020/4176376

Table 3.

MYC copy numbers regarding the analyzed clinicopathological parameters (N = 129).

Tumor
Characteristic Group MYC ≥ 2.19 (N = 55, 42.6%) MYC < 2.19 (N = 74, 57.4%) P value (chi2 test)
Age, N (%) ≤67 years 31 (56.4) 34 (45.9) 0.242
>67 years 24 (43.6) 40 (54.1)
Sex, N (%) Male 34 (61.8) 46 (62.2) 0.968
Female 21 (38.2) 28 (37.8)
Smoking status, N (%) Never 7 (12.7) 8 (10.8) 0.929
Former 29 (52.7) 41 (55.4)
Current 19 (34.6) 25 (33.8)
Histological subtypes, N (%) Adenocarcinoma 29 (52.7) 38 (51.4) 0.338
Squamous cell carcinoma 12 (21.8) 18 (24.3)
Carcinoid 4 (7.3) 10 (13.5)
LCNEC# 6 (10.9) 2 (2.7)
Other§ 4 (7.3) 6 (8.1)
Grade, N (%) Missing 5 (9.1) 8 (10.8) 0.441
G1 + G2 23 (41.8) 38 (51.4)
G3 + G4 27 (49.1) 28 (37.8)
T stage, N (%) Missing 2 (3.6) 1 (1.4) 0.092
T1 22 (40.0) 40 (54.0)
T2 25 (45.5) 20 (27.0)
T3 + T4 6 (10.9) 13 (17.6)

Fisher's exact test. #LCNEC: large-cell neuroendocrine carcinoma. §Four adenosquamous carcinomas, two non-small-cell lung cancers, one non-small-cell lung cancer (not otherwise specified), two small-cell carcinomas, and one synovial sarcoma.